A Study Of DdcfDNA For Kidney Transplant Monitoring

Overview

About this study

The purpose of this study is to clinically validate the use of GraftAssureDx as an assay for identifying kidney transplant patients with a low probability of allograft rejection.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subject is 18 years of age or older.

  • At least 12 calendar days have elapsed since the subject received a kidney transplant.

  • Subject provides legally effective informed consent.

  • Subject agrees to comply with all study procedures. 7.1.2. Subject

Exclusion Criteria:

  • Kidney donor is an identical twin of the subject.

  • The subject has another previously transplanted organ in situ.

  • Subject has received a hematopoietic stem cell transplant. 4. Subject has received a bone marrow graft.

  • Subject has self-reported as pregnant.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/06/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Mohamed Elrefaei

Open for enrollment

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available